Delcath Systems, Inc. — Form 10-Q Summary
Business context and reporting period
Delcath is an interventional oncology company focused on liver cancers. Its lead product, HEPZATO KIT, was approved by the FDA on August 14, 2023 for certain adults with unresectable hepatic-dominant metastatic uveal melanoma. CHEMOSAT, the related hepatic delivery system without melphalan, is marketed in Europe. This filing covers the three and nine months ended September 30, 2023; financial statements are unaudited.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total revenue | $0.4 million | $0.9 million | $1.5 million | $2.1 million |
| Gross profit | $0.3 million | $0.7 million | $1.1 million | $1.6 million |
| Gross margin | 69.4% | 74.1% | 69.6% | 78.4% |
| Operating loss | $(10.6) million | $(8.2) million | $(26.9) million | $(26.0) million |
| Net loss | $(20.3) million | $(8.9) million | $(36.5) million | $(28.0) million |
| Loss per diluted share | $(1.14) | $(0.96) | $(2.61) | $(3.29) |
| Operating cash flow | Not separately provided | Not separately provided | $(23.1) million | $(17.6) million |
Revenue declined 52% year over year in the quarter and 27% for the nine-month period, primarily because of lower CHEMOSAT demand. Research and development expense was $4.7 million in Q3 and $12.8 million for nine months. Selling, general and administrative expense was $6.2 million in Q3 and $15.1 million for nine months, reflecting FDA preparation and commercial launch activities.
The Q3 net loss included a $9.4 million loss from the change in fair value of warrant liabilities. Nine-month interest expense was $1.5 million, compared with $2.0 million in the prior-year period.
Liquidity, capital structure, and debt
- Cash, cash equivalents, and restricted cash were $40.5 million at September 30, 2023, compared with $11.8 million at December 31, 2022.
- Nine-month financing cash inflows were $51.8 million, including $23.0 million of private-placement proceeds and $35.0 million from warrant exercises. These inflows more than offset $23.1 million of operating cash use and $6.3 million of debt principal repayments.
- Net loans and convertible notes payable totaled $10.6 million at September 30, 2023. The Avenue loan had a 16.20% interest rate, was secured by substantially all company assets including intellectual property, and matures August 1, 2024.
- The Avenue loan's interest-only period was extended through December 31, 2023, with principal payments deferred until January 2024. The filing identifies approximately $8.6 million of loan principal payments due over the following twelve months.
- The company had $5.8 million of warrant liability and $1.3 million of contingent liability at September 30, 2023.
Material changes and unusual items
- FDA approval of HEPZATO shifted the company from primarily development activities toward U.S. commercialization and launch preparation.
- During the nine months, 9.0 million preferred shares were converted into common stock, and common shares outstanding increased to approximately 19.7 million from 10.0 million at December 31, 2022. Additional dilution may result from outstanding preferred stock, warrants, and options.
- The company recorded a non-cash $8.2 million nine-month fair-value adjustment for warrant liabilities, including $9.4 million of expense in Q3.
- Previously reported 2022 quarterly results were revised for share-based compensation. The revision increased the reported nine-month 2022 net loss by $1.7 million but did not affect cash.
- The company settled a Lachman consulting-fee dispute for $0.9 million in July 2023. A medac settlement resulted in estimated liabilities of $1.3 million, including $1.1 million classified as non-current and $0.2 million as accrued expenses.
Outlook, risks, and contingencies
Management believes existing cash will support operations through the HEPZATO launch. However, a substantial delay in commercialization or lower-than-expected revenue would require additional debt or equity financing, and the company states that it would not have sufficient funds to meet obligations within twelve months in that scenario. The filing therefore continues to disclose substantial doubt regarding the ability to continue as a going concern.
Management intends to pursue follow-on HEPZATO indications, including potential studies in metastatic colorectal cancer and cholangiocarcinoma, but timing and outcomes are uncertain. Commercial success depends on physician adoption, reimbursement, manufacturing capacity, melphalan supply, regulatory compliance, and implementation of the HEPZATO REMS program.
The filing notes that the current melphalan manufacturer received FDA Form 483 observations in an unrelated inspection and expected to suspend operations for facility maintenance beginning in December 2023. Management did not expect the suspension to affect HEPZATO supply, but acknowledges that a longer shutdown or regulatory action could create a supply interruption.
Disclosure controls were not effective as of September 30, 2023 because previously disclosed material weaknesses in internal control over financial reporting remained unremediated. The company also faces high interest rates, debt maturities, potential dilution, limited historical revenue, reimbursement uncertainty, competition, supply-chain risks, and ongoing regulatory and clinical-development risks.
Important facts for investors to verify
- Actual timing, scale, and reimbursement status of the HEPZATO commercial launch and related U.S. revenue.
- Cash-burn trajectory and whether additional financing will be required before achieving meaningful product revenue.
- January 2024 Avenue principal payments, August 2024 loan maturity, covenant compliance, and the consequences of any default.
- Melphalan availability, supplier remediation of FDA observations, and the effect of any manufacturing shutdown.
- Remaining warrant, preferred-stock, and option obligations and their potential dilution to common shareholders.
- Progress in remediating material weaknesses in internal control over financial reporting.
- Reimbursement and market adoption of CHEMOSAT in Europe and HEPZATO in the United States.